HC Wainwright Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $75.00

Sarepta Therapeutics (NASDAQ:SRPT) had its price target decreased by research analysts at HC Wainwright from $80.00 to $75.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a “sell” rating on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential downside of 41.05% from the stock’s previous close. HC Wainwright also issued estimates for Sarepta Therapeutics’ Q1 2025 earnings at $2.35 EPS, Q2 2025 earnings at $2.64 EPS, Q3 2025 earnings at $2.73 EPS, Q4 2025 earnings at $2.84 EPS and FY2025 earnings at $10.54 EPS.

A number of other analysts also recently commented on SRPT. UBS Group boosted their target price on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Barclays lowered their price target on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. StockNews.com lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Citigroup decreased their target price on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Finally, Robert W. Baird dropped their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $175.55.

Sarepta Therapeutics Stock Performance

SRPT stock traded down $0.72 during trading on Tuesday, hitting $127.23. 1,305 shares of the company traded hands, compared to its average volume of 1,240,544. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The stock’s 50-day simple moving average is $122.50 and its 200 day simple moving average is $131.48. The company has a market cap of $12.15 billion, a PE ratio of 102.36 and a beta of 0.77. Sarepta Therapeutics has a 1 year low of $83.97 and a 1 year high of $173.25.

Institutional Trading of Sarepta Therapeutics

A number of large investors have recently bought and sold shares of SRPT. Innealta Capital LLC acquired a new stake in shares of Sarepta Therapeutics in the second quarter worth approximately $31,000. Nkcfo LLC purchased a new position in Sarepta Therapeutics during the 2nd quarter valued at about $43,000. Sunbelt Securities Inc. grew its stake in shares of Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 232 shares in the last quarter. Huntington National Bank lifted its holdings in shares of Sarepta Therapeutics by 150.9% during the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after buying an additional 175 shares during the last quarter. Finally, Riggs Asset Managment Co. Inc. grew its position in Sarepta Therapeutics by 33.3% in the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 75 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.